Konorev - Corticosteroids Flashcards
(39 cards)
Adrenal CS act where?
they are ligands at nuclear receptors, translocate from cytoplasm to nucleus.
MC target cells where?
- Kidney: cells in principal cells of DcT and CD.
- Heart and vasculature: non-epithelial tissue
Action of MC in kidney.
Increase Na reabsorption/water retention.
Excess aldosterone (MC) adverse effects on heart and effects on vasculature.
- Cardiac fibrosis and hypertrophy
- Vascular remodeling and inflammation
Decreased activity (inactivating mutations) of what enzyme will cause excessive activation of MR mediated by cortisol to cause HTN and edema?
11beta-hyroxysteroid dehydrogenase, type 2
Two steroids that bind to MC-receptors with similar affinity?
aldosterone and cortisol
What converts cortisol into inactive cortisone?
11beta-hyroxysteroid dehydrogenase, type 2
Excessive activation of MR by cortisol causes what adverse effects?
HTN and edema
Three metabolic effects of excess GC
- Carbohydrate metabolism decrease - development of hyperglycemia
- Lipid metabolism increase - development of change in fat distribution (thinning of arms/legs; accumulation in upper body)
- Protein metabolism increase - myopathy and muscle wasting
GC interact with insulin in what way?
ANTI-INSULIN ACTIONS. Change gene expression in favor of lipolysis and protein breakdown = increased substrates for gluconeogenesis and HYPERGLYCEMIA.
effect GC has inflammation
decrease inflammation
effect GC has on immune system
immune suppression and decreased allergic hypersensitivity reactions.
A person has Addison’s Disease and needs replacement therapy - what combination of corticosteroids should be administered?
GC (hydrocortisone) + MC (fludrocortisone)
What three broad categories are clinical indications for CS administration?
- Replacement therapy
- Immunosuppression (transplant or immune disease)
- Inflammatory/allergic conditions (asthma, RA, IBD, etc)
AE of MCs (Fludrocortisone)
(AE of aldosterone)
- Na/H2O retention = edema, HTN
- Increased preload and hypertrophy of heart = CHF
- K+ loss and alkalosis
AE of GCs
hyperglycemia, suppressed ability to fight infections, muscle wasting and myopathy, development of striae, easy bruising, hypertension, osteoporosis, peptic ulcers, increased appetite and weight gain, retarded growth in children, glaucoma, psychiatric symptoms (euphoria, mania, anxiety)
Goals for CS dosing/admin.
- Shortest, fastest, smallest distribution and duration.
- TAPER
Do not give GC in pts with:
- Diabetes (hyperglycemia)
- Immunocompromised or with infections (suppressed ability to fight infections)
- Children (retarded growth)
- Psych conditions (euphoria, mania, anxiety)
- Cardiovascular conditions (HTN, CHF, Angina)
- Osteoperosis (post-menopausal)
- Peptic ulcers
Aminoglutethimide - Drug class, MOA
- Drug class: Steroid synthesis inhibitor
- MOA: blocks conversion of cholesterol to pregnenolone»_space; reduces production of all steroid hormones
Aminoglutethimide - Clinical indications, AE
- Clinical indications: breast cancer tx (historical), adrenocortical cancer
- AE: GI upset, drowsiness
Ketoconazole - Drug class, MOA
- Drug class: steroid synthesis inhibitor
- MOA: inhibits CYP450s; reduces synthesis of adrenal and sex hormones
Ketoconazole - Clinical indications, AE
- Clinical indications: antifungal; Cushing’s syndrome; suppression of androgenic hair loss; prostate cancer
- AE: hepatotoxicity, gynecomastia
Metyrapone - Drug class, MOA
- Drug class: steroid synthesis inhibitor
- MOA: inhibits 11-hydroxylation of steroids, selectively suppresses cortisol and cortisone production
Metyrapone - Clinical indications, AE
- Clinical indications: Cushing’s Syndrome (esp PREGNANT women)
- AE: Na/H2O retention and hirsutism in women (due to accumulation of 11-deoxycortisol); GI upset, dizziness